SunTrust Banks, Inc. reiterated their buy rating on shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in a report published on Wednesday. The firm currently has a $82.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $95.00. SunTrust Banks also issued estimates for Sage Therapeutics’ Q4 2017 earnings at ($1.54) EPS, FY2017 earnings at ($6.63) EPS, FY2018 earnings at ($5.62) EPS, FY2019 earnings at ($4.63) EPS, FY2020 earnings at ($3.04) EPS and FY2021 earnings at ($0.10) EPS.

Several other equities research analysts also recently issued reports on SAGE. ValuEngine upgraded Sage Therapeutics from a sell rating to a hold rating in a report on Friday, June 2nd. Cowen and Company initiated coverage on Sage Therapeutics in a report on Monday, June 12th. They set an outperform rating and a $95.00 price objective on the stock. Needham & Company LLC restated a buy rating and set a $82.00 price objective on shares of Sage Therapeutics in a report on Tuesday, June 13th. BidaskClub upgraded Sage Therapeutics from a buy rating to a strong-buy rating in a report on Tuesday, June 13th. Finally, Leerink Swann restated an outperform rating and set a $97.00 price objective (up from $90.00) on shares of Sage Therapeutics in a report on Tuesday, June 20th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $86.77.

Sage Therapeutics (NASDAQ:SAGE) opened at 62.36 on Wednesday. The stock’s market capitalization is $2.33 billion. Sage Therapeutics has a 52 week low of $38.30 and a 52 week high of $90.80. The firm has a 50-day moving average of $81.33 and a 200 day moving average of $74.82.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same period in the prior year, the firm posted ($1.08) earnings per share. On average, analysts anticipate that Sage Therapeutics will post ($7.38) EPS for the current year.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/17/sage-therapeutics-inc-sage-rating-reiterated-by-suntrust-banks-inc.html.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd grew its stake in Sage Therapeutics by 164.4% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 7,513 shares of the biopharmaceutical company’s stock worth $598,000 after buying an additional 4,671 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Sage Therapeutics by 19.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 497 shares during the last quarter. California State Teachers Retirement System grew its stake in Sage Therapeutics by 3.2% during the 2nd quarter. California State Teachers Retirement System now owns 61,252 shares of the biopharmaceutical company’s stock worth $4,878,000 after buying an additional 1,910 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Sage Therapeutics by 41.0% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 8,682 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 2,525 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Sage Therapeutics by 13.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,980 shares of the biopharmaceutical company’s stock worth $2,149,000 after buying an additional 3,216 shares during the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.